Overview

Dose-escalating AZD1775 + Concurrent Radiation + Cisplatin for Intermediate/High Risk HNSCC

Status:
Completed

Trial end date:
2021-06-23

Target enrollment:

Participant gender:

Summary

This open label, single-arm, Phase 1b study is designed to identify the maximum tolerated dose (MTD) using a traditional 3+3 dose escalation design of the WEE-1 inhibitor AZD1775 when added to standard of care chemotherapy (cisplatin) and radiation for the treatment of locally advanced squamous cell cancer of the head and neck (HNSCC).

Phase:

Phase 1

Details

Lead Sponsor:

UNC Lineberger Comprehensive Cancer Center

Collaborator:

AstraZeneca

Treatments:

Adavosertib
Cisplatin